Download FREE Report Sample
Download Free sampleAn anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease?2. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed) Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent.
Mesalamine Market contains market size and forecasts of Mesalamine (Lialda) in Global, including the following market information:
Global Mesalamine (Lialda) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Mesalamine (Lialda) market was valued at 161 million in 2021 and is projected to reach US$ 198.1 million by 2028, at a CAGR of 3.0% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Enemas Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Mesalamine (Lialda) include Dr.Falk Pharma, Ferring, Ethypharm Pharmaceutical, Shanghai Pharmaceutical, Tillotts Pharma, Holy Stone Healthcare, Giuliani, Zeria and Lupin, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Mesalamine (Lialda) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Mesalamine (Lialda) Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Mesalamine (Lialda) Market Segment Percentages, by Type, 2021 (%)
Enemas
Tablets
Suppositories
Other
Global Mesalamine (Lialda) Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Mesalamine (Lialda) Market Segment Percentages, by Application, 2021 (%)
Colitis
Crohn's Disease
Proctitis
Diarrheal Irritable Bowel Syndrome
Diverticulitis
Other
Global Mesalamine (Lialda) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Mesalamine (Lialda) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Mesalamine (Lialda) revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Mesalamine (Lialda) revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Dr.Falk Pharma
Ferring
Ethypharm Pharmaceutical
Shanghai Pharmaceutical
Tillotts Pharma
Holy Stone Healthcare
Giuliani
Zeria
Lupin
Heilongjiang Tianhong Pharmaceutical
HENGCHENG PHARMACEUTICAL
KWAI FA Pharmaceutical Group
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
